<DOC>
	<DOCNO>NCT00787605</DOCNO>
	<brief_summary>The purpose study evaluate blood pressure lower effect safety aliskiren combination Hydrochlorothiazide ( HCTZ ) give diabetic patient stage 2 systolic hypertension ( mean sit systolic blood pressure ( msSBP ) ≥ 160 mm Hg &lt; 200 mm Hg ) .</brief_summary>
	<brief_title>Aliskiren HCTZ Compared Amlodipine Patients With Stage 2 Systolic Hypertension Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female outpatient ≥ 18 year old . 2 . Patients diagnosis stage 2 hypertension ( defined office cuff msSBP ≥ 160 mmHg &lt; 200 mmHg ) Visit 5 ( randomization ) . 3 . Patients diabetes mellitus ( Type 2 ) HbA1c visit 1 ≤ 9.0 % currently stable antidiabetic regimen stable diet exercise least 4 week prior visit 1 . 4 . Patients eligible able participate study , willing give write informed consent assessment perform . Exclusion criterion : 1 . Office blood pressure measure cuff ( msSBP ≥ 200 mmHg msDBP ≥ 110 mmHg ) Visits 15 . 2 . History evidence secondary hypertension etiology ( e.g. , uncorrected renal artery stenosis , pheochromocytoma ) . 3 . History hypertensive encephalopathy heart failure ( NYHA Class IIIV ) . 4 . Cerebrovascular accident , transient ischemic cerebral attack ( TIA ) , coronary bypass surgery , myocardial infarction percutaneous coronary intervention ( PCI ) within 1 year prior Visit 1 . 5 . Serum sodium less low limit normal , serum potassium &lt; 3.5 mEq/L ( correspond 3.5 mmol/L ) ≥ 5.3 mEq/L ( correspond 5.3 mmol/L ) , dehydration Visit 1 . 6 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) . 7 . Use investigational drug within 30 day enrollment . 8 . History hypersensitivity study drug drug belong therapeutic class ( thiazide diuretic , renin inhibitor , calcium channel blocker , dihydropyridine like calcium channel blocker ) study drug . 9 . History gouty arthritis . 10 . Long QT syndrome QTc &gt; 450 msec male &gt; 470 msec female screen . 11 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 12 . Women childbearing potential , defined woman physiologically capable become pregnant include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS use two birth control method . The two method double barrier method barrier method plus hormonal method . Adequate barrier method contraception include : diaphragm , condom ( partner ) , intrauterine device ( copper hormonal ) , sponge spermicide . Hormonal contraceptive include market contraceptive agent include estrogen and/or progestational agent . Reliable contraception maintain throughout study 7 day study drug discontinuation . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) six month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL ( estradiol &lt; 20 pg/mL ) surgical bilateral oophorectomy ( without hysterectomy ) least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . 13 . Known KeithWagener grade III IV hypertensive retinopathy . 14 . Current angina pectoris require pharmacological therapy ( except sublingual nitroglycerin ) . 15 . Second third degree heart block without pacemaker . 16 . Atrial fibrillation atrial flutter Visit 1 , potentially lifethreatening symptomatic arrhythmia 12 month prior Visit 1 . 17 . Clinically significant valvular heart disease . 18 . History angioedema use ACE inhibitor . 19 . History evidence drug alcohol abuse within last 12 month . 20 . Any surgical medical condition , opinion investigator , may place patient high risk his/her participation study , likely prevent patient comply requirement study complete study . 21 . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug include , limited , follow : History major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection . History active inflammatory bowel disease 12 month prior Visit 1 . Currently active gastritis , duodenal gastric ulcer , gastrointestinal bleed 3 month prior Visit 1 . Any history pancreatic injury , pancreatitis , evidence impair pancreatic function/injury indicate abnormal lipase amylase 12 month prior Visit 1 . Evidence hepatic disease determine one following : ALT AST value exceed 3 x ULN Visit 1 , history hepatic encephalopathy , history esophageal varix , history portocaval shunt . Evidence renal impairment determine one following : serum creatinine &gt; 1.5 x ULN Visit 1 , history dialysis , history nephrotic syndrome . Current treatment cholestyramine colestipol resins 22 . History noncompliance medical regime unwillingness comply study protocol . 23 . Any condition opinion investigator would confound evaluation interpretation efficacy and/or safety data . 24 . Persons directly involved execution protocol . 25 . Known contraindication study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Hypertension , diabetes mellitus , aliskiren , hydrochlorothiazide , systolic blood pressure , diastolic blood pressure , amlodipine , stage 2</keyword>
</DOC>